Glucotrack, Inc. (NASDAQ:GCTK) has commenced preclinical animal testing for its implantable continuous glucose monitor (CGM). The company previously announced positive results from a laboratory-based feasibility study. The preclinical study established that the sensor implant procedure takes approximately 15-20 minutes to perform, does not require sophisticated implant techniques or tools, and had no adverse short-term or long-term effect on the animals. Long-term preclinical studies on sensor performance are expected to start in late Q4 of this year.